- The scientific article in the peer-reviewed journal Clinical and Translational Gastroenterology describes obefazimod's capacity to selectively up-regulate a single microRNA, miR-124, leading to decreases in proinflammatory cytokines and thus acting as "a physiological brake" of inflammation and to impact the immune system in vitro, in murine models of inflammatory bowel disease (IBD), as well as in patients suffering from ulcerative colitis (UC)
- Obefazimod is a once-daily orally administered small molecule which is currently in Phase 3 clinical trials for the treatment of UC (ABTECT program)
PARIS, FRANCE / ACCESSWIRE / January 5, 2023 / Abivax SA (Euronext Paris: FR0012333284: - BVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announced the publication of a scientific article in the peer-reviewed journal Clinical and Translational Gastroenterology (CTG) entitled: "ABX464 (obefazimod) up-regulates miR-124 to reduce pro-inflammatory markers in inflammatory bowel diseases." 
The publication highlights obefazimod's novel mechanism of action (MoA) and its capacity to treat patients with moderate to severe UC. The article extends the observations reported in Abivax's previous publications on the Phase 2a and Phase 2b clinical trials conducted in UC, including patients who failed to respond or stopped responding to currently available therapies.
The article reports that obefazimod has been observed to impact the immune system in vitro , in murine models of IBD, as well as in patients with UC. The up-regulation of a single microRNA, miR-124, in vitro shows that obefazimod's MoA leads to decreases in proinflammatory cytokines including IL-17 and IL-6, and in the chemokine CCL2/MCP-1, thereby potentially putting "a physiological brake" on inflammation. It reverses the expression of several inflammatory cytokines without impairing host defense as it does not impact the immune response altogether. These scientific findings may explain its short- and long-term efficacy along with a favorable tolerability and safety profile which were observed during the clinical Phase 2a and Phase 2b induction and maintenance clinical trials conducted in UC patients.
Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: "Abivax feels very encouraged by the data published in our article and the validation and extension of obefazimod's novel and potent anti-inflammatory mechanism of action. The data complement our scientific findings released on our clinical Phase 2a and Phase 2b induction and maintenance results which were generated with obefazimod for the treatment of patients with moderate to severe ulcerative colitis. The article once again supports the rationale that our lead molecule has the potential to efficiently, durably and safely treat UC patients. This specific MoA acts through the upregulation of a specific anti-inflammatory microRNA which reduces the expression of several pro-inflammatory cytokines. Consequently, the excessive immune response leading to the chronic inflammation of the bowel may be balanced through a continued treatment with obefazimod. We believe that obefazimod has the potential to also become an effective long-term therapy for other chronic inflammatory diseases with high medical need."
Abivax believes obefazimod is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miR-124) with potent anti-inflammatory properties. Obefazimod was shown to exert its anti-inflammatory effects through binding to the cap binding complex ("CBC"), which sits at the 5' end of every RNA molecule in the cell. By binding to the CBC, obefazimod reinforces the biological functions of CBC in cellular RNA biogenesis. Specifically, obefazimod enhances the selective splicing of a single long non-coding RNA to generate the anti-inflammatory microRNA, miR-124, which downregulates the translation of pro-inflammatory cytokines and chemokines like TNF-α, IL-6, CCL2/MCP-1 and IL-17, as well as Th17+ cells. This downregulation thereby potentially "puts a brake" on inflammation and suggests broad potential as a novel anti-inflammatory therapeutic agent. Laboratory analysis of the Phase 2b trial in UC at week eight showed a highly statistically significant upregulation of miR-124 in rectal tissue in all patients treated with obefazimod, compared to baseline. The median increases were 13-fold for the 25 mg group, 25-fold for the 50 mg group and 25-fold for the 100 mg group, while no upregulation was observed in the placebo group (1.02-fold increase), indicative of the positive pharmacological effect of obefazimod. Importantly, obefazimod does not impact the splicing of cellular genes.
Obefazimod for the treatment of adults with moderate to severe ulcerative colitis
Obefazimod is currently in Phase 3 clinical trials for the treatment of ulcerative colitis ("ABTECT program") with the first patient enrolled in the United States on October 11, 2022.
1,200 UC patients across 36 countries will take part in the pivotal Phase 3 program that consists of two induction trials (ABTECT-1 (ABX464-105) and ABTECT-2 (ABX464-106)) and a single subsequent maintenance trial (ABX464-107).
The ABTECT program aims to confirm obefazimod's potential to maintain and further improve patient-outcomes over time, as well as its favorable safety and tolerability profile, as already observed during previously conducted Phase 2a and Phase 2b clinical trials in moderate to severe UC.
About Abivax (www.abivax.com)
Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at www.abivax.com . Follow us on Twitter @ABIVAX_.
+33 6 24 50 69 63
+44 7413 825310
Press Relations &
MC Services AG
+49 211 529 252 22
Public Relations France
+33 6 21 10 49 24
Public Relations France
Thomas Roborel de Climens
+33 6 78 12 97 95
Public Relations USA
Rooney Partners LLC
+1 646 770 8858
This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although Abivax' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.
 Apolit et al.: ABX464 (obefazimod) up-regulates miR-124 to reduce pro-inflammatory markers in inflammatory bowel diseases, CTG, published online Jan. 2023.